NEW YORK, September 27, 2017 /PRNewswire/ --
If you want a Stock Review on NEOT, PIRS, or RPRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, September 26, 2017, US markets saw three out of nine sectors finishing the day in green, five in red, and one in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,380.16, up 0.15%; the Dow Jones Industrial Average edged 0.05% lower, to finish at 22,284.32; and the S&P 500 closed at 2,496.84, up 0.01%. This Wednesday morning, DailyStockTracker.com looks at the performance of these three Biotechnology stocks: Neothetics Inc. (NASDAQ: NEOT), Pieris Pharmaceuticals Inc. (NASDAQ: PIRS), and Repros Therapeutics Inc. (NASDAQ: RPRX). This morning's free research reports on the aforesaid equities can be accessed upon registration on DailyStockTracker.com at:
http://dailystocktracker.com/register/
Neothetics
On Tuesday, shares in San Diego, California headquartered Neothetics Inc. recorded a trading volume of 1.17 million shares, which was above their three months average volume of 943.39 thousand shares. The stock ended the session 9.94% higher at $0.44. The Company's shares have gained 20.31% in the last month. The stock is trading above its 50-day moving average by 6.49%. Moreover, shares of Neothetics, which develops therapeutics for the aesthetic market, have a Relative Strength Index (RSI) of 64.29. Visit us today and download your complete report on NEOT for free at:
http://dailystocktracker.com/registration/?symbol=NEOT
Pieris Pharmaceuticals
Shares in Boston, Massachusetts headquartered Pieris Pharmaceuticals Inc. recorded a trading volume of 132,064 shares. The stock ended yesterday's trading session 1.14% lower/ higher at $5.31. The Company's shares have advanced 11.79% over the previous three months, 216.07% in the past twelve months, and 277.88% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.09% and 50.84%, respectively. Furthermore, shares of Pieris Pharma, which discovers and develops Anticalin-based drugs, have an RSI of 50.52. Register for free on DailyStockTracker.com and download the research report on PIRS at:
http://dailystocktracker.com/registration/?symbol=PIRS
Repros Therapeutics
The Woodlands, Texas-based Repros Therapeutics Inc.'s stock finished Tuesday's session 0.20% lower at $0.30 with a total trading volume of 105,809 shares. The stock is trading below its 50-day moving average by 8.57%. Additionally, shares of Repros Therapeutics, which focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the US, have an RSI of 42.98. Get free access to your research report on RPRX at:
http://dailystocktracker.com/registration/?symbol=RPRX
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
Advertisement
If you want a Stock Review on NEOT, PIRS, or RPRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, September 26, 2017, US markets saw three out of nine sectors finishing the day in green, five in red, and one in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,380.16, up 0.15%; the Dow Jones Industrial Average edged 0.05% lower, to finish at 22,284.32; and the S&P 500 closed at 2,496.84, up 0.01%. This Wednesday morning, DailyStockTracker.com looks at the performance of these three Biotechnology stocks: Neothetics Inc. (NASDAQ: NEOT), Pieris Pharmaceuticals Inc. (NASDAQ: PIRS), and Repros Therapeutics Inc. (NASDAQ: RPRX). This morning's free research reports on the aforesaid equities can be accessed upon registration on DailyStockTracker.com at:
Advertisement
http://dailystocktracker.com/register/
Neothetics
On Tuesday, shares in San Diego, California headquartered Neothetics Inc. recorded a trading volume of 1.17 million shares, which was above their three months average volume of 943.39 thousand shares. The stock ended the session 9.94% higher at $0.44. The Company's shares have gained 20.31% in the last month. The stock is trading above its 50-day moving average by 6.49%. Moreover, shares of Neothetics, which develops therapeutics for the aesthetic market, have a Relative Strength Index (RSI) of 64.29. Visit us today and download your complete report on NEOT for free at:
http://dailystocktracker.com/registration/?symbol=NEOT
Pieris Pharmaceuticals
Shares in Boston, Massachusetts headquartered Pieris Pharmaceuticals Inc. recorded a trading volume of 132,064 shares. The stock ended yesterday's trading session 1.14% lower/ higher at $5.31. The Company's shares have advanced 11.79% over the previous three months, 216.07% in the past twelve months, and 277.88% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.09% and 50.84%, respectively. Furthermore, shares of Pieris Pharma, which discovers and develops Anticalin-based drugs, have an RSI of 50.52. Register for free on DailyStockTracker.com and download the research report on PIRS at:
http://dailystocktracker.com/registration/?symbol=PIRS
Repros Therapeutics
The Woodlands, Texas-based Repros Therapeutics Inc.'s stock finished Tuesday's session 0.20% lower at $0.30 with a total trading volume of 105,809 shares. The stock is trading below its 50-day moving average by 8.57%. Additionally, shares of Repros Therapeutics, which focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the US, have an RSI of 42.98. Get free access to your research report on RPRX at:
http://dailystocktracker.com/registration/?symbol=RPRX
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
